• Cutia Therapeutics posted a net loss of RMB 180.4 million, narrowing from a year earlier; loss per share improved to RMB 0.5.
• Revenue fell 5.4% to RMB 62.7 million due to terminating distribution and agency partnerships for some scalp and routine skin care products.
• Gross profit dropped 54.7% to RMB 14.5 million; gross margin slid 25 percentage points to 23% on the same one-off impact.
• Selling and distribution expenses decreased 37.4% to RMB 57.4 million, helped by lower share-based payments, headcount, and marketing spend.
• Commercial rollout expanded for Finjuve and Amzeeq since late October 2025; CU-30101 won NMPA authorization in May 2026 ahead of launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12307907), on August 31, 2026, and is solely responsible for the information contained therein.